BAUSCH HEALTH COMPANIES INC

Company Overview

Bausch Health is a diversified specialty pharmaceutical and medical device company operating five reportable segments (Salix, International, Solta Medical, Diversified and Bausch + Lomb) with global commercial reach in ~90 countries. In 2024 it generated $9.625B of revenue, with Bausch + Lomb representing roughly half of sales and Xifaxan alone contributing about $2.0B, while the company runs ~75 R&D programs and spent ~$616M on R&D. The business model mixes internal R&D and manufacturing (≈35 owned sites, some single-sourced active ingredients) with M&A, licensing and co-promotion to refresh the pipeline, and is exposed to regulatory, pricing (IRA/CMS negotiation) and litigation (Paragraph IV/generic) risks as well as substantial net leverage (~$21.6B).

Executive Compensation Practices

Given the company’s profile, pay is likely to emphasize near-term commercial performance (segment revenue and contribution margins for Bausch + Lomb and Salix/Xifaxan), cash generation and deleveraging metrics (operating cash flow, debt reduction and successful refinancing or asset monetization). Long‑term incentives in this industry typically combine equity (RSUs/options) tied to multi‑year TSR or relative performance with milestone/transaction awards for M&A or separations—here, management will likely see specific vesting tied to a successful Bausch + Lomb separation, completion of major refinancing steps, and patent/litigation outcomes. Annual bonuses are probably weighted toward revenue growth, margin expansion and working‑capital improvement, while R&D/program milestones (approvals, launches) and supply‑chain continuity may factor into incentive payouts for product and operations leaders.

Insider Trading Considerations

Insider transactions at Bausch Health will be particularly informative around regulatory and litigation catalysts (FDA/EMA approvals, Paragraph IV rulings, CMS/IRA negotiation results for Xifaxan), material M&A or separation steps for Bausch + Lomb, and refinancing or covenant developments given the high leverage. Watch for trading clustered near quarter results, refinancing announcements (e.g., April 2025 refinancing and subsequent note redemptions), recall/resolution news (enVista IOL), or major supply disruptions from single‑source suppliers—these are moments when insiders may reveal private views. Standard regulatory constraints apply (Section 16 reporting/Form 4, blackout windows, possible 10b5‑1 plans), but in a highly leveraged, regulation‑intensive drug manufacturer, contemporaneous sales by insiders can reflect either routine tax/liquidity needs or important signals about confidence in near‑term deleveraging and litigation outcomes—so interpret sales and buys in context of the company’s debt, pipeline and pending corporate actions.